Skip to content
Patients
HCPs
X-twitter Instagram Youtube Icon-mail Tiktok
Follow on X
Home
Daily Updates

Categories

Parkinson’s disease as a somato-cognitive action network disorder.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This study examines how a specific brain network—the somato-cognitive action network (SCAN)—relates to Parkinson’s...

Continue ReadingParkinson’s disease as a somato-cognitive action network disorder.

Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This publication is a narrative review on cancer vaccines in lung cancer, focused on overcoming resistance to immune che...

Continue ReadingLung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives.

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:1 min read

This publication describes the creation of the APOLLO11 consortium, a nationwide Italian network focused on lung cancer,...

Continue ReadingAPOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:1 min read

Phase III TASUKI-52: 4-year outcomes Population & design - Untreated advanced nonsquamous NSCLC. - Randomized 1:1 t...

Continue ReadingFour-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This publication is a podcast-style discussion on current management of metastatic ALK‑positive NSCLC, with an emphasi...

Continue ReadingFirst Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.

Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This phase III randomized superiority trial compared ultra-low-dose nivolumab with standard single-agent chemotherapy (d...

Continue ReadingEfficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).
  • © Together4Cancer. All rights reserved.
  • Privacy Policy
  • Terms of Use